acid reflux retatrutide Unapproved weight loss drug causes extreme side effects #retatrutide

Accessed on April 25, 2023 at Mayo Clinic

In exploratory research, retatrutide represents the most ambitious incretin agent currently available

The reduction in oestrogen typically causes a redistribution of adipose tissue from peripheral sites (hips and thighs) to central abdominal areas, increasing visceral fat accumulation

GLP-1 agonism delivers central appetite suppression and glucose-dependent insulin release

Median time (T max ) to maximal concentration (C max ) values ranged from 2.0 to 6.0 hours post-dose

"These are the most significant weight loss numbers ever seen with a pharmaceutical treatment of obesity," said Dr